Clene

Clene Capital Intensity

The Capital Intensity Ratio of Clene (CLNN) as of Nov 16, 2026 is 9,065.50 %. In the previous year, Capital Intensity Ratio was 7,993.27 % — a change of 13.41% (higher).

Capital Intensity

9,065.50 %

YoY

13.41%

Last updated:

Capital Intensity Ratio of Clene is 2025 9,065.50 % . Capital Intensity Ratio of Clene was 2024 7,993.27 % . It decreases by 13.41% higher compared to the previous year.

The Clene Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2020
33,127.67 USD
Jan 1, 2021
8,722.41 USD
Jan 1, 2022
9,406.55 USD
Jan 1, 2023
8,003.21 USD
Jan 1, 2024
7,993.27 USD
Jan 1, 2025
9,065.50 USD
The Clene Capital Intensity history
YEARCapital IntensityYoY
9,065.50 %+13.41%
7,993.27 %-0.12%
8,003.21 %-14.92%
9,406.55 %+7.84%
8,722.41 %-73.67%
33,127.67 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clene Stock analysis

What does Clene do? Clene Inc develops therapeutic products for neurodegenerative diseases, focusing on targeting energetic failure as a root cause. Its primary product CNM-Au8 is an oral suspension of gold nanocrystals designed to restore neuronal health by enhancing energy production and utilization. The company also develops CNM-ZnAg, a spectrum antiviral and antibacterial agent containing zinc and silver ions for infectious disease treatment and immune support, and CNM-AgZn17, a gel polymer suspension of zinc and silver for wound healing and infectious disease management. These products are intended for clinical development and eventual commercialization in the pharmaceutical market. Clene's target customers are patients suffering from neurodegenerative diseases and infectious conditions requiring antiviral, antibacterial, or wound healing solutions. The company's products aim to address unmet medical needs in these therapeutic areas by leveraging innovative nanocrystal and ion-based technologies. The firm operates within the biopharmaceutical sector, developing treatments that focus on cellular energy processes to provide neuroprotection and remyelination. The company generates revenue through the development and potential future commercialization of its drug candidates. CNM-Au8 targets neurodegenerative diseases by addressing energetic failure, while CNM-ZnAg and CNM-AgZn17 focus on infectious disease treatment and wound healing applications. These products are in clinical development stages, with the company seeking to advance them toward regulatory approval and market entry. Clene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clene stock

Capital Intensity Ratio of Clene is 9,065.50 % in 2025.

Capital Intensity Ratio of Clene changed from 7,993.27 % to 9,065.50 %, representing a 13.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Clene since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Clene with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Clene

All Key Metrics — Clene